United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in...

|About: United Therapeutics Corpora... (UTHR)|By:, SA News Editor

United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells.